Boehringer, Click Therapeutics investigational prescription digital therapeutic meets primary endpoint in study for schizophrenia

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-10 06:30 GMT | Update On 2025-08-10 06:30 GMT

Boehringer Ingelheim and Click Therapeutics have announced that the pivotal Phase III CONVOKE study (NCT05838625) of CT-155 (BI 3972080), an investigational prescription digital therapeutic (PDT), met its primary endpoint.

The randomized, double-blind, controlled study investigated the effectiveness and safety of CT-155 versus a digital control app as an adjunct to standard of care antipsychotic therapy in people diagnosed and living with schizophrenia experiencing negative symptoms. The study’s primary endpoint was change in experiential negative symptoms from baseline to week 16 as measured by the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP).

In the CONVOKE study, CT-155 was well tolerated and demonstrated a favorable safety profile consistent with past studies.

“The positive results from the CT-155 pivotal trial are an important moment for people living with the negative symptoms of schizophrenia,” said Emmanuelle Clerisme-Beaty, Medical Director US, SVP Medicine, Boehringer Ingelheim Pharmaceuticals, Inc.. “Although treatments are being used to help manage negative symptoms, there are no U.S. regulatory authority-approved treatments indicated for the negative symptoms of schizophrenia to date. This is one of the largest unmet needs for these patients and those who care for them. We are proud to work in partnership with multiple stakeholders and innovative partners like Click Therapeutics on this journey.”

Approximately 2.8 million adults in the U.S. live with schizophrenia, which places a profound burden on individuals, families and society. About 60% of people living with schizophrenia experience negative symptoms.

“Findings from CONVOKE provide the first Phase III evidence supporting the potential of a prescription digital therapeutic as an adjunct to standard of care antipsychotic therapy to treat a core element of schizophrenia,” said Shaheen Lakhan, MD, PhD, FAAN, chief medical and scientific officer of Click Therapeutics. “The observed clinical benefit on experiential negative symptoms in this study, without additional known safety concerns, marks a critical advancement in understanding how we might address this long unmet need.”

Detailed results will be presented during the Novel Therapeutics Symposium on Monday, October 13 at the 38th Annual European College of Neuropsychopharmacology (ECNP) Congress being held in Amsterdam, The Netherlands.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Boehringer, Click Therapeutics investigational prescription digital therapeutic meets primary endpoint in study for schizophrenia

Similar News

Zydus Lifesciences Slapped Rs 3.35 Crore Tax Demand Over CENVAT Credit

Surat Businessman Arrested in Rs 8.5 Crore Pharma Fraud, Probe on Accomplices

Relief Sought for Small Retailers as GST 2.0 Sparks Losses in Pharma Trade

MSN Lab gets CDSCO panel nod for Phase IV CT of Tofacitinib Oral Solution

Health Ministry Bans 34 Key Antibiotics, Antivirals for Animal Use, See List

Sun Pharma exposed to some headline risk amid US tariff move, but with limited earnings impact

Intas Pharma appoints Akash Kalal as General Manager - API Production

Sun Pharma, Zydus and 3 others recall products in US